NeuroXess

NeuroXess announced that its self-developed implantable brain-computer interface system for hand motor function compensation — the 'fully implanted, fully wireless, fully functional' ('Sanquan') system — has passed public notice and formally entered the innovative medical device special review program of the National Medical Products Administration's Center for Medical Device Evaluation (CMDE), commonly known as the green channel. The company describes it as the first subdural implantable flexible BCI product in China to enter the program. The system began a GCP registration clinical trial at Huashan Hospital, Fudan University on July 7, 2026, run as a multicentre study across 15 Class III hospitals nationwide, with trial data intended to support a Class III medical device registration application with the NMPA. The system remains in the review and clinical-trial stage and has not yet been approved for market; the registration timeline reflects company statements and remains subject to regulatory notice.

NeuroXess said two people with high-level paralysis played chess against each other across about 800 kilometers, between Shanghai and Nanchang in eastern China, using its "Triple-Full" (三全) brain-computer interface: one selected and placed pieces on a virtual board by thought, with the commands relayed in real time to a robot stand-in that moved the pieces at the other end, where the second participant gripped physical pieces through a brain-controlled exoskeleton glove. The company said the first participant was implanted at Huashan Hospital, Fudan University, in October 2025, moved a cursor by thought on the fifth day after surgery and reached 5.2 bits per second after 17 days of training, while the second was implanted at the First Affiliated Hospital of Nanchang University in December 2025 and was eating, drinking and writing with a brain-controlled exoskeleton one month after surgery. The outcomes come from the vendor's own account and have not been validated in peer-reviewed publication.